Amedeo Smart

Free Medical Literature Service

 

Amedeo

Biliary Tract Diseases
  Free Subscription

Articles published in
J Gastroenterol
    June 2026
  1. MIZUNO K, Chretien B, Nishida K, Ito T, et al
    Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.
    J Gastroenterol. 2026 Jun 26. doi: 10.1007/s00535-026-02469.
    >> Share

  2. SOUSA JM, Rodriguez-Tajes S, Hernandez-Guerra M, Casado M, et al
    Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02442.
    >> Share

  3. SUTO H, Kumamoto K, Nagao M, Furuichi Y, et al
    Paired tumor-normal metabolomic profiling reveals alterations in choline phospholipid precursor metabolism in biliary tract cancer.
    J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02471.
    >> Share

  4. MOL B, van Munster K, Weersma R, Inderson A, et al
    The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study.
    J Gastroenterol. 2026 Jun 15. doi: 10.1007/s00535-026-02449.
    >> Share

  5. OZMERT EH, Yee SK, Ilyas SI, Smoot RL, et al
    Emerging omics diagnosis of perihilar cholangiocarcinoma.
    J Gastroenterol. 2026 Jun 12. doi: 10.1007/s00535-026-02453.
    >> Share

    May 2026
  6. SHIBUKI T, Hoyek C, Ramaker R, Gottam M, et al
    Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.
    J Gastroenterol. 2026 May 25. doi: 10.1007/s00535-026-02439.
    >> Share

    April 2026
  7. KO SW, Oh D, Song TJ
    Evolution of gallbladder drainage: a comprehensive review from percutaneous to endoscopic ultrasound-guided approaches.
    J Gastroenterol. 2026 Apr 24. doi: 10.1007/s00535-026-02417.
    >> Share

  8. KOSAKA H, Sugimoto R, Kinoshita M, Yasuda S, et al
    Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.
    J Gastroenterol. 2026 Apr 12. doi: 10.1007/s00535-026-02412.
    >> Share

  9. OKA Y, Sakai A, Masuda A, Sofue K, et al
    Prospective pilot study of functional assessment of the Sphincter of Oddi via cine-dynamic MRCP with selective inversion recovery pulse.
    J Gastroenterol. 2026;61:487-495.
    >> Share

    March 2026
  10. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    >> Share

    February 2026
  11. NAITOH I, Nakazawa T, Notohara K, Inoue D, et al
    Clinicopathological features of localized-type IgG4-related cholecystitis: a nationwide multicenter study in Japan.
    J Gastroenterol. 2026 Feb 25. doi: 10.1007/s00535-026-02353.
    >> Share

    January 2026
  12. SHEN L, Lv T, Li S, Chen S, et al
    Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jan 13. doi: 10.1007/s00535-025-02342.
    >> Share

    November 2025
  13. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Correction: Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Nov 26. doi: 10.1007/s00535-025-02329.
    >> Share

  14. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    >> Share

    October 2025
  15. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    >> Share

  16. ZHU M, Douchi D, Murakami K, Itoh T, et al
    Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02303.
    >> Share

    September 2025
  17. KOBAYASHI S, Nakachi K, Yamamoto K, Ueno M, et al
    Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).
    J Gastroenterol. 2025 Sep 6. doi: 10.1007/s00535-025-02294.
    >> Share

    June 2025
  18. NAITOH I, Isayama H, Akamatsu N, Mizuno S, et al
    The 2024 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2025 Jun 12. doi: 10.1007/s00535-025-02265.
    >> Share

    May 2025
  19. ZHU J, Chen H, Meng L, Jiang J, et al
    Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.
    J Gastroenterol. 2025 May 5. doi: 10.1007/s00535-025-02234.
    >> Share

    April 2025
  20. YOSHIDA M, Toyohara T, Hori Y, Kato A, et al
    Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02250.
    >> Share

    February 2025
  21. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Correction: Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2025 Feb 27. doi: 10.1007/s00535-025-02217.
    >> Share

  22. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    >> Share

    November 2024
  23. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2024 Nov 27. doi: 10.1007/s00535-024-02183.
    >> Share

  24. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    >> Share

  25. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    >> Share

    August 2024
  26. TAKAOKA S, Hamada T, Nakai Y, Yasunaga H, et al
    Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation".
    J Gastroenterol. 2024 Aug 6. doi: 10.1007/s00535-024-02143.
    >> Share

    July 2024
  27. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    >> Share

    June 2024
  28. TAKAOKA S, Hamada T, Takahara N, Fukuda R, et al
    Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation.
    J Gastroenterol. 2024 Jun 19. doi: 10.1007/s00535-024-02124.
    >> Share

    May 2024
  29. KANO Y, Ishikawa T, Yamao K, Mizutani Y, et al
    What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?
    J Gastroenterol. 2024 May 7. doi: 10.1007/s00535-024-02105.
    >> Share

    March 2024
  30. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    >> Share

    October 2023
  31. WU JF, Peng SS, Tai CS, Lin WH, et al
    The magnetic resonance imaging and age-adjusted matrix metalloproteinase-7 assist the diagnosis of biliary atresia.
    J Gastroenterol. 2023 Oct 30. doi: 10.1007/s00535-023-02051.
    >> Share

  32. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    >> Share

    September 2023
  33. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    >> Share

    July 2023
  34. FUJITA N, Yasuda I, Endo I, Isayama H, et al
    Evidence-based clinical practice guidelines for cholelithiasis 2021.
    J Gastroenterol. 2023 Jul 15. doi: 10.1007/s00535-023-02014.
    >> Share

  35. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    >> Share

    June 2023
  36. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    >> Share

  37. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    >> Share

    May 2023
  38. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016